CALYM
CALYM is a French non-profit academic consortium accelerating R&D on lymphoid neoplasms through public-private partnerships. It serves pharmaceutical, biotech, and academic medical centers via four interconnected technology platforms covering the full R&D value chain from biomarker discovery to Phase III trials.
- Company typePrivate
- Founded2011
- HeadquartersParis, France
- Headcount—
- GTM typeB2B
- OfferingServices
What CALYM does
CALYM is a French non-profit association (loi 1901) operating since 2011 as an academic research consortium dedicated to accelerating R&D on lymphoid neoplasms — including lymphomas, lymphoid leukemias, and now, following a 2026 scope expansion, myelomas. The organization holds the Carnot Institute label granted by the French Ministry of Higher Education, Research and Innovation, and coordinates an ecosystem of 18 laboratories of excellence plus, as of 2026, 20 research entities including the internationally recognized cooperative groups LYSA (lymphoma clinical research), Lysarc (first European operational structure for lymphoma clinical research), and IFM (myeloma research across France, Belgium, and Switzerland). Industrial partnership revenues have grown from €11M to €45M over 15 years at greater than 10% annual rates, with ~80% of revenues coming from major international pharmaceutical groups and a stated 2030 target of €100M.
CALYM operates four interconnected technology platforms that span the full R&D value chain from biomarker discovery through Phase III clinical trials. HEMSYS is a free web application for hematology multidisciplinary tumor board meetings (RCP) deployed in 14+ centers with 40,000+ patients, 78,000+ records, and 100+ disease-specific forms. French Connect is a multi-center liquid biopsy platform for ctDNA-based minimal residual disease monitoring across 10 academic centers in France and Switzerland. The Lymphoma Data Hub (LDH) is a cloud platform aggregating 8+ TB of clinical, omics, and imaging data across 17 data types and supporting 8 active AI-driven projects. CeVi is a national biobanking network of 13 ISO 20387-certified centers providing cryopreserved viable lymphoma cells and a simplified regulatory framework for cohort construction.
CALYM's business model is anchored in collaborative R&D partnerships with pharmaceutical and biotechnology companies, supplemented by French SMEs, academic medical centers, and patient advocacy groups such as ELLyE. Industrial sponsors — including Roche, Bristol-Myers Squibb (4-year ATLAS project), and AstraZeneca (HERmathology initiative) — engage CALYM through direct enterprise sales leveraging the consortium's Carnot credentials and academic network, while AI and blockchain partners (Euranova, Embleema, Microsoft via TA4H) provide technology capabilities. The HEMSYS platform is provided free of charge to hematology departments as a freemium adoption mechanism that feeds data and case volume back into the consortium. Go-to-market combines dedicated R&D partnership teams, scientific conferences (SFH, EHA, ESMO AI), the RedTalks webinar series, the Déchocage patient-focused podcast, and targeted communication partnerships such as the 2025 alliance with Edimark. CALYM is directed by Bertrand Nadel (also an Inserm research director at Centre d'Immunologie de Marseille-Luminy) and coordinated by Pr. G. Cartron at CHU Montpellier.
CALYM firmographics
Firmographics- Name
- CALYM
- Legal name
- Association CALYM
- Website
- https://calym.org
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Short description
- CALYM is a French non-profit academic consortium accelerating R&D on lymphoid neoplasms through public-private partnerships. It serves pharmaceutical, biotech, and academic medical centers via four interconnected technology platforms covering the full R&D value chain from biomarker discovery to Phase III trials.
- Ownership category
- akta.pro rank
CALYM industry classification
Industry- Product category
- Hematology R&D Partnership Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171), Medical and Diagnostic Laboratories (6215)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF)
- akta.pro secondary industries
- Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM), Clinical Research & Trial Central Laboratories (HLAFAMAL), Translational Medicine & Biomarkers (HLAIALAF), Cell-Based & Potency Assays (Bioassays) (HLAGADAH)
Keywords
Where CALYM is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
CALYM business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Contract Research Services: CALYM generates revenue through collaborative R&D partnerships with pharmaceutical companies, biotechs, and medtech companies. Contractual research revenues have grown from €11M to €45M over 15 years (4x growth), with ~80% from major international pharma groups and targeted support for French SMEs and biotechs. The target is €100M in partnership revenues by 2030.
- Academic Partnership Programs: CALYM participates in national programs including France 2030, PEPR (Strategic Programs for Innovation), and the Health Industries Technologies Committee (ITS), generating funding and collaborative research opportunities.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Others | Free access to hematology departments |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels8 records
CALYM product offering
Product offeringCore offering
CALYM is an academic research consortium (Institut Carnot CALYM) that operates four interconnected technology platforms — HemSys, French Connect, Lymphoma Data Hub (LDH), and CeVi — to provide collaborative R&D partnership services in lymphoid neoplasms. It connects pharmaceutical companies, biotechs, medtech firms, and academic medical centers to accelerate research from biomarker discovery through Phase III clinical trials. The consortium is coordinated across 18+ research laboratories and leading cooperative groups (LYSA, Lysarc, IFM) under the Carnot label awarded by the French Ministry of Higher Education, Research and Innovation.
Product overview
CALYM operates as a consortium offering four interconnected technological platforms for lymphoid neoplasm research. HemSys is a dedicated RCP (multidisciplinary tumor board) web application structuring hematology consultations across 14+ centers. French Connect provides liquid biopsy ctDNA analysis for MRD monitoring with standardized NGS panels. The Lymphoma Data Hub (LDH) serves as a cloud-based data platform aggregating clinical, omic, and imaging data for AI-driven research. CeVi offers cryopreserved cell biobanking with certified centers across France. These platforms work together to support the full R&D value chain from biomarker discovery through Phase III clinical trials.
Differentiator
Problem solved
Functional benefit
Brands
- HemSys: Web application for Multidisciplinary Team Meetings (RCP) in hematology, providing structured patient data collection and documentation for clinical decision-making.
- French Connect
- LDH (Lymphoma Data Hub)
- CeVi
Products and services
- HemSys
Quantifiable outcome
- 4x revenue growth in 15 years (€11M to €45M) with >10% annual growth rate
- +3 more outcomes
Companies that use CALYM
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles3 records
CALYM technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature4 records
CALYM partnerships and signals
Strategic signalPartnerships
14 partnerships are on record, tiered core and supporting.
- UNITCcoreUNITC is a national consortium for cell and gene therapies in which CALYM serves as a founding member. Together with UNITC and France BioLead, CALYM organized a national CAR in vivo trajectory development workshop gathering over 100 experts to advance France's position in in-vivo CAR-T cell therapies.
- France BioLeadcoreFrance BioLead is a federating network in biotherapies and bioproduction from France 2030, serving as initiator and coordinator of the CAR in vivo national trajectory in collaboration with CALYM/UNITC. The partnership aims to build a complete dossier for French CAR in vivo development.
- EdimarksupportingEdimark is a recognized scientific and medical communication specialist in editorial and audiovisual content for healthcare professionals. The partnership aims to strengthen visibility of CALYM network research and innovations nationally.
- LYSAcoreIndependent network of expert professionals and international leader in clinical research on lymphoma and chronic lymphocytic leukemia. LYSA is one of CALYM's foundational cooperative groups driving major advances in lymphoma treatment.
- LysarccoreFirst European operational structure for clinical research on lymphoma and CLL, operating as a foundational cooperative group within the CALYM consortium.
- IFM (Intergroupe Francophone du Myélome)coreCooperative group of expert clinicians and biologists specializing in myeloma across France, Belgium, and Switzerland, conducting fundamental, translational, and clinical research. Five new entities including IFM are joining CALYM in 2026.
- Paris-Saclay Cancer Cluster (PSCC)supportingPartnership between Carnot institutes OPALE and CALYM with Paris-Saclay Cancer Cluster to accelerate onco-hematology research and support therapeutic innovation, launched during September Rouge.
- EmbleemasupportingBlockchain-based patient consent management for clinical studies and regulatory-compliant evidence generation through HIVE big data platform, used by FDA and CDISC for cell and gene therapy standards.
- EuranovasupportingAI-powered medical imaging solutions for lymphoma diagnosis, including automated pathological data generation and therapy decision support through advanced artificial intelligence.
- Bristol-Myers Squibb (BMS)coreATLAS project: 4-year public-private collaboration building a cellular 'ATLAS' of biological parameters associated with tumor transformation, growth, relapse, and treatment resistance, using CeVi biological samples and LYSA clinical expertise.
- AstraZenecasupportingHERmathology initiative partnership supporting the Women in Lymphoma global study on gender equity in hematology leadership, clinical trials access, and mentorship across 34 countries.
- ELLyE (Ensemble Leucémie Lymphomes Espoir)supportingPatient association partnership for lymphoma research advocacy, including Dr. Nadel's appearance on Déchocage podcast to discuss follicular lymphoma, patient journey, and innovation sovereignty.
- MicrosoftsupportingTA4H project: Structured data extraction from multidisciplinary team meetings (RCP) using free-text analysis through Microsoft technology partnerships.
- INSERMcoreNational research collaboration including RIBB, PEPR, and INSERM partnerships for CAR in vivo national trajectory development and spatial omics research (SpatialOmics project).
Scale indicators11 records
Recent moves7 records
Expansion highlights6 records
CALYM competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
CALYM social profiles
Digital presenceCALYM compliance and trust
Trust signalCompliance1 record
CALYM financial estimates
Financial estimateRevenue estimate
Valuation estimate
CALYM leadership team
Management profileNumber of profiles
Profiles3 records
CALYM funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CALYM M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CALYM
What does CALYM do?
CALYM is an academic research consortium (Institut Carnot CALYM) that operates four interconnected technology platforms — HemSys, French Connect, Lymphoma Data Hub (LDH), and CeVi — to provide collaborative R&D partnership services in lymphoid neoplasms. It connects pharmaceutical companies, biotechs, medtech firms, and academic medical centers to accelerate research from biomarker discovery through Phase III clinical trials. The consortium is coordinated across 18+ research laboratories and leading cooperative groups (LYSA, Lysarc, IFM) under the Carnot label awarded by the French Ministry of Higher Education, Research and Innovation.
Is CALYM a public or private company?
CALYM is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was CALYM founded?
CALYM was founded in 2011.
Where is CALYM based?
CALYM is headquartered in Paris, France, in the Europe region.
How does CALYM make money?
Two revenue lines are on record. Contract Research Services are the primary driver. The others are academic Partnership Programs.
Does CALYM have an API?
No public API is recorded for CALYM.
What industry is CALYM in?
CALYM's product category is Hematology R&D Partnership Services. Its primary akta.pro industry code is HLAGAAAF, Clinical Data Management, Biostatistics & Statistical Programming CROs, with a secondary code of HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF). Its NAICS code is 541714 and its SIC code is 8731.